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Abstract: Clostridium difficile (C. difficile) is a problematic Gram positive bacterial pathogen causing 
moderate to severe gastrointestinal infections. Based on a lead binaphthyl-tripeptide dicationic 
antimicrobial, novel mono-, di-and tri-peptidomimetic analogues targeting C. difficile were designed and 
synthesized incorporating one, two or three D-configured cationic amino acid residues, with a common 
1,2,3-triazole ester isostere at the C-terminus. Copper- and ruthenium-click chemistry facilitated the 
generation of a 46 compound library for in vitro bioactivity assays, with structure-activity trends over the 
largest compound subset revealing a clear advantage to triazole-substitution with a linear or branched 
hydrophobic group. The most active compounds were dicationic-dipeptides where the triazole was 
substituted with a 4- or 5-cyclohexylmethyl or 4,5-diphenyl moiety, providing MICs of 4 µg mL-1 against 
three human isolates of C. difficile. Further biological screening revealed significant antimicrobial activity 
for several compounds against other common bacterial pathogens, both Gram positive and negative, 
including S. aureus (MICs ≥2 µg mL-1), S. pneumoniae (MICs ≥1 µg mL-1), E. coli (MICs ≥4 µg mL-1), 
A. baumannii (MICs ≥4 µg mL-1) and vancomycin-resistant E. faecalis (MICs ≥4 µg mL-1). 
 
Introduction 
Unique antibacterial molecules with new modes of action are currently in high demand for the 
treatment of antibiotic-resistant bacterial infections.1 In particular, the Gram positive, gastric 
anaerobe Clostridium difficile has been recently listed as the number one bacterial threat in the 
USA.2 C. difficile produces potent toxins which cause symptoms such as diarrhea, abdominal pain 
and pseudomembranous colitis (PMC) upon gastrointestinal infection.3−5 C. difficile infection 
(CDI) occurs in up to 20% of patients given conventional oral antibiotic therapy due to 
elimination of the commensal, gastrointestinal microflora.3,4 High morbidity and up to an 8% 
mortality rate highlights the seriousness of this disease, with both the severity and incidence 
increasing due to epidemics of hypervirulent strains.3−5 Further, the nosocomial nature of the 
infection and the persistence of C. difficile spores results in a major health problem and a serious 
financial burden to the healthcare sector (>$1 billion/year in the USA alone).5 
Traditional medications for the treatment of CDI (vancomycin and metronidazole) are 
inadequate as reinfection occurs in 15−35% of patients.3,4 Fidaxomicin was approved by the Food 
and Drug Administration in 2011 for the treatment of CDI, exhibiting a decrease in recurrence 
relative to that of vancomycin and metronidazole.6,7 Potential CDI chemotherapeutics are 
currently under various stages of development, these include REP3123,8 nitazoxanide,9 fusidic 
acid,5 teicoplanin,5,10 LFF571,11 CB-183 31512 and cationic nylon-3 polymers.13 Furthermore, 
monoclonal antitoxin antibodies are under investigation as potential treatments for CDI 
recurrence.7 This intense interest in novel CDI therapeutics is a direct result of the inadequacy of 
current medications, the continuing cost to the healthcare sector and the emergence of 
hypervirulent strains. 
Previous research in our laboratory has led to the development of a promising new class of 
antimicrobials based upon a binaphthyl-tripeptide structure (e.g., 1, Fig. 1).14−16 These derivatives 
exhibit selective inhibition of Gram negative bacteria, as well as broad-spectrum activity against 
Gram positive bacteria including vancomycin-, linezolid- and methicillin-resistant strains.14−16 
Efficacy has been translated in vivo, both topically and systemically, for infections of the latter.14 
A rudimentary pharmacophore has emerged comprising an anchoring (semi)rigid aromatic core 
(binaphthyl/biphenyl), two cationic residues and a hydrophobic moiety at the peptide C-
terminus.14−16 
With a continuing interest in expanding the applications of these binaphthyl-based 
antimicrobials, we were inspired to investigate their potential as chemotherapeutics for CDI. We 
envisioned that the non-drug-like features and high molecular weight of these molecules would 
ensure limited oral bioavailability, making them ideal candidates for the treatment of 
gastrointestinal infections. Initial inspiration came from preliminary in vitro testing of 1 against C. 
difficile, which exhibited a promising minimum inhibitory concentration (MIC) of 8 µg mL-1 
against two problematic ribotype 027 strains. This is the first example of this class of compounds 
inhibiting an anaerobic bacterial strain. Therefore, this lead compound formed the basis of this 
current study, which aimed to replace the terminal ester with a peptidomimetic 1,2,3-triazole 
moiety17 for increased metabolic stability in the gut.18 We report here the synthesis and 
antimicrobial activities of forty six novel binaphthyl-1,2,3-triazole peptide derivatives, resulting 
in the identification of several promising compounds with improved activity against C. difficile 




Fig. 1 Antibacterial compound 1 developed previously in our laboratory.14 
 
Results and Discussion 
The synthetic binaphthyl-1,2,3-triazole peptides for this investigation were divided into three 
target classes (A−C) based on the number of embedded amino acid residues (Fig. 2). Class A was 
the starting point for our molecular design, given that is an isostere analogue of our existing 
broad-spectrum antibacterials which incorporate three amino acid residues (e.g., ester 1). Smaller 
peptide classes B and C, bearing two and one amino acid residues respectively, were chosen as 
additional targets to establish the necessary components for activity against C. difficile and other 
bacterial pathogens. Within classes A and C, we also planned to perform minor variations in the 
amino acid identity at AA1 and AA3. A cationic arginine was to be maintained as the second 
residue (AA2) throughout.14−16 Our previous studies have shown that all stereoisomers of 1 have 
similar activity,14 thus we aimed to incorporate the unnatural D-configured cationic residues due to 
an expected increase in enzymatic stability.19 
 
Fig. 2 Binaphthyl-triazole peptide classes (A−C) synthesized in this study. 
 
An overview of our proposed synthetic strategy is shown in Scheme 1, exemplified with a Class 
B scaffold. The peptide backbone would be assembled from the N-terminus by the iterative 
coupling of protected amino acid and amino azide components, resulting in a net-replacement of 
the C-terminus with an azide moiety. This modular approach would allow variation of the number 
and type of amino acid residues incorporated, enabling straightforward access to all three target 
classes. The terminal triazole ester isostere, common to all target peptides, could then be 
assembled by cycloadditions with alkynes and arynes. Finally, basic amino functionalities would 
be revealed as their hydrochloride salts by acidolysis of the Boc and 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) protecting groups.  
 
 
Scheme 1 Brief overview of the synthesis of cationic triazole peptides, exemplified with a Class B scaffold. 
 
In addition to the prevalence of 1,2,3-triazole-containing antibacterials,20 this heterocyclic motif 
offers clear advantages in terms of synthetic possibilities, given its reliable access via metal-
catalyzed azide-alkyne click chemistry.21 This atom economical cycloaddition is arguably the 
most efficient of all click processes, offering a high yielding, regioselective and functionally 
tolerant entry to 1,2,3-triazoles. Thus, strategic incorporation of click chemistry at the penultimate 
stages of our syntheses should permit rapid, divergent access to new heterocyclic derivatives 
based on readily available alkynes, enabling a thorough structure-activity exploration at the 
peptide termini (R1 and R2). A variety of conditions (A−E, Fig. 3) were adapted from the 
literature for the cycloadditions conducted throughout this study, including ruthenium-catalyzed 
variants to reverse the regiochemistry obtained by conventional copper catalysis.22−26 
 
Fig. 3 Conditions for azide−alkyne cycloadditions used in this study.22−26 
 
The synthesis of Class A compounds began with the coupling of lysine-based acid 214 and 
protected arginine ester 3,27  giving dipeptide 4 in 92% yield after saponification (Scheme 2a). 
This intermediate was coupled with leucine-derived amino azide 528 and separately, the novel 
arginine-derived amino azide 14 (Scheme 2b) to give terminal azides 6 and 15, respectively, in 
near quantitative yields. Excess amine (1.5−2.0 equiv) was necessary during these reactions to 
avoid competitive consumption of 4 via intramolecular attack of its protected guanidine on the 
activated acid, which occurred as a side reaction under stoichiometric conditions.  
With azide 6 in hand, copper-catalyzed click reactions (conditions A, Fig. 3) with selected 
terminal alkynes proceeded smoothly to produce triazoles 7−9 in 63−93% yields (Scheme 2a). 
The hydrophobic nature of the binaphthyl-azide constituted the need for a 4:1 t-BuOH:H2O binary 
 
 
solvent, as opposed to the standard 1:2 t-BuOH:H2O more polar medium.
22 The quantities of 
inexpensive reagents: alkyne, Cu(OAc)2 and Na·ascorbate were not optimized due to the small 
scale of the reactions (<0.1 mmol of azide). Prior to deprotection of the leucine-containing Class 
A compounds, alcohol 7 was converted to its methyl ether derivative 10. Subsequent treatment of 
8−10 with TFA, followed by anion exchange with ethereal HCl, afforded dihydrochloride salts 
11−13 (Scheme 2a; insert). Similarly, a tricationic Class A derivative 17 was prepared in good 
overall yield via cycloaddition of 15 with 5-methyl-1-hexyne (Scheme 2b). 
i) MsCl, NEt3, CH2Cl2, 0 °C
ii) MeOH, NaHMDS





































































































































1) TFA, CH2Cl2, rt
2) HCl in Et2O
16: 87% R3 = Boc, R4 = R5 = Pbf
17: 84% R3 = R4 = R5 = H HCl
10: 63% R2 = O
H2N
NN
11 13: 76 91%
R3 = R4 = H HCl
8: 93% R2 =
9: 93% R2 =
7: 63% R2 = OH
R3 = Boc
R4 = Pbf8 10
1) TFA, CH2Cl2, rt









Scheme 2 Synthesis of Class A triazoles bearing three amino acid residues. 
 
 
Scheme 3 Synthesis of Class B triazoles bearing two amino acid residues. See Table 1 for specific click conditions and yields.
 
Class B triazoles precursor 18 was obtained in multigram quantities by the coupling of acid 214 
with 14 (Scheme 3). Cycloaddition reactions were then carried out under a range of conditions as 
summarized in Table 1. All unsymmetrically substituted non-fused triazoles (R1 ≠ R2) were 
formed with >95% regiochemical purity as determined by NMR analysis. A diverse set of 1,4-
disubstituted triazoles (R1 = H, R2 ≠ H) were obtained by copper-catalyzed conditions A,22 which 
accommodated a number of terminal alkynes including functionalized versions and those 
substituted with primary alkyl, tertiary alkyl, cyclic and aryl hydrocarbons. Under conditions A, 
good to excellent yields were obtained throughout, with the exception of the electron-poor methyl 
propiolate, which afforded triazole ester 38 in a moderate 56% yield (Table 1, entry 20). 
Silylacetylenes reacted slowly under the copper catalyzed conditions and afforded mixtures 
containing de-silylated products. Therefore, thermal Huisgen cycloaddition was used for these 
substrates, allowing the sterically controlled installation of trimethylsilyl (TMS) and 
dimethylphenylsilyl groups at R2 in high yields (conditions C, entries 9 and 10).24 
The 1,5-regioisomers (R1 ≠ H, R2 = H) of selected Class B triazoles were prepared by Ru(II) 
catalysis in 70−82% yield (conditions B, Table 1, entries 3, 7 and 12).23 Notable differences in the 
NMR spectra were observed in comparison to their previously prepared regioisomers. For 
example, the lone triazole proton (R2 = H) of compound 30 (entry 12) appeared as a singlet at 7.69 
ppm in the 1H NMR spectrum, in contrast to its 1,4-regioisomer 29 (entry 11) in which this proton 
(R1 = H) resonated at 8.06 ppm. Ru(II) activation was also suitable for internal alkyne 
diphenylacetylene,29 providing a fully substituted triazole 40 in excellent yield (entry 22). 
Additionally, a halogen was introduced at C-5 (R1) of the triazole ring through CuI mediated 
cycloaddition of 1-iodo-phenylacetylene and 18 (conditions D, entry 23).25 
Fused benzotriazole 42 was synthesized via the cycloaddition of azide 18 with in situ generated 
benzyne (conditions E, Table 1, entry 24).26 This protocol was also extended to a heteroaryne, 
producing the indole-fused triazole 43 in a reasonable 58% yield, albeit as an approximate 2:1 
mixture of regioisomers (entry 25). The structure of the major isomer could not be determined due 
to poor resolution of regioisomeric peaks in the 1H NMR spectrum, however it is noteworthy that 
a previous indolyltriazole formed in this manner showed moderate preference for azide attack 
(triazole N-1) at the indole 5-position (2.4:1 isomeric ratio).30 Commercially available pyridyne 
precursors were also screened in this (hetero)aryne cycloaddition, however, with the need to 
utilize azide 18 as the limiting reagent, pyridine polymerization31 occurred almost exclusively 





Table 1 Conditions & yields for the preparation of Class B triazoles via cycloaddition of azide 18 with alkynes and arynes. 
 
Entry R1 R2 Conda Prod Yield (%) 
1 H A 19 90 
2 H A 20 67 
3 
 
H B 21 74 
4 H A 22 94 
5 H A 23 82 
6 H A 24 93 
7  H B 25 70 
8 H A 26 99 
9 H C 27 93 
10 H C 28 96 
11 H A 29 90 
12 
 
H B 30 82 
13 H 
 
A 31 87 
14 H A 32 79 
15 H A 33 85 
16 H A 34 81 
17 H OH A 35 92 
18 H A 36 75 
19 H A 37 87 
20 H A 38 56 
21 H A 39 78 
22 
 
B 40 94 
23 I D 41 85 
24b 
         
E 42 81 
25b 
   
E 43 58 
a See Fig. 3 for reaction conditions. b Prepared by reaction with the appropriate (hetero)aryne. 
 
Although the preferred regiochemical outcome of conditions A−D could be confidently inferred 
from literature precedent,22−25 we were able to confirm the expected orientations of representative 
triazoles 28, 30, 31 and 41 by two-dimensional HSQC and HMBC NMR experiments (Fig. 4). In 
each case, a through-bond correlation between the methylene hydrogens adjacent to the triazole 
and C-5 of the ring provided unequivocal evidence of the assigned structure.  
 
Fig. 4 Key NMR through-bond H−C correlations used to confirm the regiochemistry of representative Class B triazoles. 
a Spectra acquired for deprotected derivative. 
 
With the exception of triazole ester 38, all Class B triazoles documented in Table 1 were 
converted to their corresponding hydrochloride salts 44−67 in an average yield of 87% (Scheme 
3). Selected click products from this Class B set (in protected form) were also used to access 
further derivatives as shown in Schemes 4−6. Unsubstituted triazole 69 was obtained through the 
desilylation of compound 27 with TBAF (Scheme 4). Removal of the TMS group was extremely 
slow, requiring 7 d at rt to give intermediate 68 in 91% yield. 
 
Scheme 4 Synthesis of unsubstituted Class B triazole 69. 
 
Further Class B ether derivatives 77−83, unattainable from commercially available alkynes via 
click chemistry, were synthesized in a divergent fashion from alcohol 35 (Scheme 5). The 
mesylate ester derivative was treated with preformed alkoxides or phenoxide using NBu4I as an 
additive, giving penultimate protected ethers 70−76 in 41−85% yield. The efficiency of this 
etherification generally decreased with increasing length of the alkyl chain. It should be noted that 
compound 75 was also prepared in 79% yield by the copper catalyzed click reaction of azide 18 
with pre-synthesized i-heptyl propargyl ether (reaction not shown). This more convergent 
approach could prove superior for future scale-up of a selected compound, but would have proven 
synthetically more cumbersome if used to access all desired ether derivatives.  
 
 
Finally, Class B ester 38 was used for the synthesis of amide derivatives after saponification to 
carboxylic acid 84 (Scheme 6). Initially, we were surprised to find that neither our standard 
EDCI·HCl/HOBt coupling conditions nor a HATU/(i-Pr)2NEt system were successful for amide 
bond formation, resulting in recovery of unreacted starting materials. Eventually, we found that 
acid 84 could be activated as a mixed anhydride,32 although excess reagents were necessary to 
obtain synthetically useful yields of the desired amides. 
 
Scheme 5 Synthesis of additional Class B triazole ethers. a Etherification conditions: PhOH, Cs2CO3, MeCN, rt. 
 
 
Scheme 6 Synthesis of Class B triazole amides. 
 
After establishing an extensive set of Class B triazoles, we turned our attention to the synthesis 
of monocationic Class C compounds; details are given in Scheme 7. The required lysine and 
arginine-based azides 91 and 98 were readily obtained by the coupling of acid 8914 with amino 
azides 9033 and 14, respectively. Each azide was then subjected to copper catalyzed cycloadditions 
with a small set of previously employed hydrophobic alkynes (Table 2). Interestingly, 
cycloadditions of lysine-derived azide 91 with benzyl and isopentyl-substituted alkynes were 
rather slow; heating to 35 °C for 46−48 h was required for complete azide consumption (Table 2, 
entries 2 and 3), in contrast to the arginine analogue 98, which reacted completely at rt within 24 
h. This reactivity difference revealed a theretofore hidden accelerating effect of the remote 
guanidine moiety, presumably by coordination to the copper catalyst. 
 
 
Scheme 7 Synthesis of Class C triazoles bearing one amino acid residue. See Table 2 for specific click conditions and yields. 
 
Table 2 Conditions and yields for the preparation of Class C triazoles via cycloaddition of azides 91 and 98 with various 
alkynes. 
 
Entry AA1 R2 Conda Prod Yield (%) 
1 Lys(Boc) 
 
A 92 92 
2 Lys(Boc) 
 
Ab 93 79 
3 Lys(Boc) 
 
Ab 94 72 
4 Arg(Pbf) 
 
A 99 98 
5 Arg(Pbf) 
 
A 100 85 
6 Arg(Pbf) 
 
A 101 98 
7 Arg(Pbf)  A 102 79 
8 Arg(Pbf)  A 103 89 




In vitro bacterial testing results for the three triazole classes A−C are presented in Tables 3−5, 
respectively. Lead compound 1 was included as a positive control throughout, in addition to 
vancomycin and chloramphenicol for Gram positive and Gram negative strains, respectively. 
Three C. difficile human isolates were evaluated including 027 ribotypes from Canada (M7404) 
and the UK (R20291).34  
Our initial results with Class A tripeptides 11−13 were encouraging (Table 3, entries 2−4) and 
established that antibacterial activity across the eight strains tested was not adversely affected by 
incorporation of the triazole ester isostere. A direct comparison between leucine-containing 
triazole 13 and ester 1, which both contain a terminal isopentyl group, revealed similar or 
identical potency against C. difficile and the majority of other strains tested (entry 4 versus entry 
1). Our laboratory had yet to examine the effect of a third cationic residue incorporated into the 
peptide backbone, however this modification ultimately resulted in a slight decrease in C. difficile 
activity (entry 5). 
Improved antimicrobial activity was observed for several Class B dipeptides in comparison to 
their Class A counterparts. Good to excellent activity was observed across Gram positive S. 
aureus, E. faecalis and S. pneumoniae strains (Table 4, entries 2−35), with equivalent potency to 
previously optimized lead compound 1 in many cases. 1,4-Disubstituted triazoles and their 1,5-
regioisomers generally exhibited comparable activity; for example, cyclohexylmethyl 
regioisomers 49 and 50 returned identical MICs across seven of the eight strains tested (Table 4, 
entries 8 and 9). A notable structure-activity trend was observed for dialkyl ether derivatives 
77−82 (entries 20−25). Namely, when the length of the terminal alkyl chain was increased 
beginning with a methyl ether (entry 20), a corresponding increase in activity was observed across 
all strains until reaching optimal potency with an isopentyl or isohexyl terminus (entries 23 and 
24). No further benefit was accrued from further elongation of the alkyl chain (entry 25). 
Analysis of C. difficile testing results from Class B derivatives revealed a clear activity 
dependency upon triazole substitution with a hydrophobic moiety (Table 4). Aryl, alkyl and silyl-
based groups were all conducive to good activity, while the incorporation of polar functional 
groups such as an alcohol (Table 4, entry 19), amides (entries 29−30) and an ammonium cation 
(entry 31) led to decreased C. difficile inhibition. A notable exception to this trend was a 4-
butylphenyl substituent (entry 15), which showed relatively weak activity overall. Reduced C. 
difficile activity was also observed with unsubstituted triazole 69 (entry 2) and the propyl 
derivative 44 (entry 3), highlighting the general requirement of a larger and/or branched 
hydrophobic group. The most potent Class B triazoles were 49, 50 and 64, bearing 4-
cyclohexylmethyl, 5-cyclohexylmethyl and 4,5-diphenyl substituents, respectively (Table 4, 
entries 8, 9 and 32). These compounds inhibited C. difficile growth at a concentration of only 4 µg 
mL-1 across all three strains examined, thus approaching the efficiency observed for vancomycin 
(MIC = 2 µg.mL-1, Table 4, entry 36). None of the ether derivatives tested had MICs lower than 8 
µg mL-1 against C. difficile (entries 20−27). 
 
Table 3 Antibacterial activity of Class A triazoles as minimum inhibitory concentrations (MICs) in µg mL-1. 
 























1 1 - - 8 8 8 16 2 2 2 2 
2 11 Leu CH2OMe 16 16 16 16 4 4 4 8 
3 12 Leu Propyl 8 8 8 8 2 4 4 8 




i-Pentyl 16 8 16 16 2 4 4 8 
6 vancomycin - - 2 2 2 - 1 1 4 0.5 
7 chloramphenicol - - - - - 4 - - - - 
 
A related dependence on hydrophobic termini also emerged from the testing of Class B 
compounds against Gram negative E. coli (Table 4). Triazole substituents such as isopentyl, 
cyclohexyl, TMS and benzyl provided optimal MICs of 4 µg mL-1 (entries 4, 5, 7, 11 and 17), 
representing a four-fold increase in potency relative to that of compound 1. 
Class C compounds with a single amino acid residue were also active against C. difficile, with 
MICs ranging from 4−16 µg mL-1 (Table 5, entries 2−9). Strong bacterial inhibition was also 
maintained for Gram positive S. aureus and E. faecalis strains. Class C triazoles derived from 
arginine were generally more active than their lysine-based analogues; for instance, comparison 
of phenyl-substituted triazoles 95 and 104 derived from lysine and arginine, respectively, showed 
at least a two-fold increase in potency for the latter for six out of the eight strains tested (Table 5, 
entry 2 versus entry 5). Notably, Class C triazoles were completely inactive against E. coli, 
establishing the need for two basic side chains for Gram negative activity.  
Selected Class B compounds bearing hydrophobic termini were also tested against additional 
bacterial isolates (Table 6). Similar to compound 1, good to excellent activity was observed across 
 
 
all strains including Gram negative A. baumannii and Gram positive vancomycin-resistant E. 
faecalis (VRE) strains. Comparison of Class B data for VRE (Table 6) to that obtained for 
vancomycin-susceptible E. faecalis (Table 4), shows that MICs are largely the same or one 
dilution different, suggesting that vancomycin resistance does not have a significant impact on 
susceptibility to the triazole compounds. 
The ease of synthetic access to this class of binaphthyl-triazole peptides has allowed ready 
scale-up for impending in vivo studies on CDI. For instance, 0.56 g of Class B triazole 49 and 
0.67 g of Class C triazole 104 have been prepared. Preliminary toxicity screening has also 
provided promising results. Our most active compounds (i.e., 49, 50 and 64, Table 4) exhibited 
<3% hemolysis of sheep erythrocytes at concentrations above their C. difficile MICs (5 µg mL-1, 
Tables S3−S5 in electronic supplementary material). 
Although the precise antimicrobial mechanism of our binaphthyl-peptides has not yet been fully 
elucidated, the observation that all three compound classes A−C were active suggests a general 
mode of action. Related cationic peptides have been shown to operate via a membrane 
depolarization mechanism.35 Resistance studies with C. difficile are in progress within our 
laboratories to identify a potential binding target for our newly developed molecules. 
Table 4 Antibacterial activity of Class B triazoles as minimum inhibitory concentrations (MICs) in µg mL-1. 
 
Entry Compound R1 R2 
C. difficile E. coli 
ATCC 
25922 
















1 1 - - 8 8 8 16 2 2 2 2 
2 69 H H 32 32 32 64 4 4 8 2 
3 44 H Propyl 16 16 16 16 2 2 4 8 
4 45 H i-Pentyl 16 16 8 4 2 2 2 1 
5 46 i-Pentyl H 8 8 8 4 2 2 2 4 
6 47 H n-Hexyl 8 4 8 8 2 2 2 4 
7 48 H Cy 8 8 8 4 2 2 2 2 
8 49 H CH2Cy 4 4 4 8 2 2 2 4 
9 50 CH2Cy H 4 4 4 8 2 4 2 4 
10 51 H t-Bu 8 8 8 8 2 2 4 4 
11 52 H SiMe3 8 8 8 4 2 2 2 1 
12 53 H SiMe2Ph 8 8 8 8 2 4 2 4 
13 54 H Ph 16 16 16 8 2 2 2 2 
14 55 Ph H 8 8 8 4 2 2 2 4 
15 56 H 4-(n-Bu)-Ph 32 32 16 64 8 4 4 16 
16 57 H 4-OMe-Ph 8 16 8 16 2 2 4 4 
17 58 H Bn 8 8 8 4 2 2 2 4 
18 59 H CH2CH2Ph 8 8 8 8 2 4 2 4 
19 60 H CH2OH 32 32 32 64 8 8 8 8 
20 77 H CH2OMe 32 32 32 32 8 8 8 8 
21 78 H CH2O(i-Pr) 32 32 32 32 4 4 8 4 
22 79 H CH2O(i-Bu) 16 16 16 8 2 2 4 4 
23 80 H CH2O(i-Pent) 8 8 8 4 2 2 2 4 
24 81 H CH2O(i-Hex) 8 8 8 4 2 2 2 8 
25 82 H CH2O(i-Hept) 8 8 8 16 4 4 4 8 
26 83 H CH2OPh 8 8 8 8 4 2 4 4 
27 61 H CH2OBn 16 16 16 4 2 2 2 2 
28 62 H OEt 16 16 16 16 4 4 4 4 
29 87 H CO(Morph) 16 16 16 16 4 4 8 8 
30 88 H CONH(i-Bu) 16 16 16 8 2 4 4 4 
31 63 H (CH2)2NH2·HCl 32 32 16 64 4 4 8 4 
32 64 Ph Ph 4 4 4 16 4 4 4 4 
33 65 I Ph 8 8 8 16 4 4 4 4 
34 66 Benzo(triazole)a 16 16 16 8 2 2 2 4 
35 67 Indolyl(triazole)b 16 8 8 16 2 4 4 8 
36 vancomycin - - 2 2 2 - 1 1 4 0.5 
37 chloramphenicol - - - - - 4 - - - - 




Table 5 Antibacterial activity of Class C triazoles as minimum inhibitory concentrations (MICs) in µg mL-1. 
 
Entry Compound AA1 R2 
C. difficile E. coli 
ATCC 
25922 
















1 1 - - 8 8 8 16 2 2 2 2 
2 95 Lys Ph 16 16 16 >128 4 8 4 32 
3 96 Lys Bn 8 8 8 >128 4 4 4 32 
4 97 Lys i-Pentyl 16 16 16 128 8 8 4 32 
5 104 Arg Ph 8 8 4 >128 2 2 4 8 
6 105 Arg Bn 8 8 8 128 2 2 4 16 
7 106 Arg i-Pentyl 8 8 8 128 2 2 4 16 
8 107 Arg Cy 8 8 8 >128 2 2 4 8 
9 108 Arg CH2Cy 16 16 16 >128 4 4 4 8 
10 vancomycin - - 2 2 2 - 1 1 4 0.5 
11 chloramphenicol - - - - - 4 - - - - 
 
  
Table 6 Further biological screening of selected Class B compounds. Results given as minimum inhibitory concentrations 
(MICs) in µg mL-1. 
 
Entry Compound R1 R2 















1 1 - - 4 8 2 2 4 4 
2 45 H i-Pentyl 4 4 2 2 4 4 
3 46 i-Pentyl H 4 4 2 2 4 4 
4 47 H n-Hexyl 4 4 2 2 4 4 
5 49 H CH2Cy 8 4 2 2 4 4 
6 52 H SiMe3 8 8 4 1 8 4 
7 54 H Ph 8 8 2 2 4 4 
8 55 Ph H 4 4 4 2 8 8 
9 59 H CH2CH2Ph 8 8 2 2 8 4 
10 81 H CH2O(i-Hex) 4 4 4 2 4 4 
11 61 H CH2OBn 8 4 4 2 8 8 
12 64 Ph Ph 4 4 2 4 8 4 
13 65 I Ph 8 8 2 4 4 4 
14 vancomycin - - - - 8 2 128 64 
15 ciprofloxacin - - 1 0.25 - - - - 
 
Conclusions 
In conclusion, we have prepared forty six triazole ester isostere analogues of the antibacterial 
dicationic tripetide 1, with the aim of developing metabolically more stable molecules suitable for 
targeting C. difficile infections in the gut. These analogues were synthesized employing Cu- or 
Ru-catalyzed click chemistry which allowed for regioselective variations of substituents at C-4 
and C-5 (R1 or R2) of the triazole moiety. Dicationic-tripeptide and dipeptide mimetics were 
prepared along with a series of monocationic-monopeptide analogues, incorporating unnatural D-
amino acids in most cases.  
Significantly, the dicationic-tripeptide analogues (Class A compounds) had similar antibacterial 
activity as the lead compound 1 against a select panel of Gram positive and Gram negative 
bacteria and were effective (MICs of 8 µg mL-1) against three strains of C. difficile, including two 
problematic ribotype 027 strains. The larger set of dicationic-dipeptide analogues (Class B 
 
 
compounds) provided useful SAR data and identified three significant compounds (49 (R2 = 
CH2Cy), 50 (R
1 = CH2Cy) and 64 (R
1 = R2 = Ph)) with MICs of 4 µg mL-1 against the three C. 
difficile strains, only one broth dilution different from the positive control vancomycin (MIC of 2 
µg mL-1). SAR studies indicated that linear or branched hydrocarbon chain substituents (>4 
carbons) at C-4 and/or C-5 (R1 or R2) of the triazole provided compounds with the highest 
activities against the eight bacterial strains, while compounds with more polar substituents (short 
chain ethers, alcohol, amide or ammonium ion) were less effective. Interestingly, some of the 
structurally much simpler monocationic-monopeptides (Class C compounds) were just as active 
as compound 1 against most Gram positive strains, while a complete loss of Gram negative E. coli 
activity was observed for all monocationic compounds.  
In addition to the promising antimicrobial activity of these peptidomimetics, their 
straightforward synthetic access via amide coupling and click chemistry, based on an inexpensive 
binaphthyl scaffold, makes them attractive candidates for the treatment of CDI. These 
encouraging results have prompted in vivo studies of these compounds in mouse models which 
are underway. Additionally, the significant C. difficile inhibition observed for diphenyl triazole 
64, in particular, presents further synthetic opportunities to be explored including click chemistry 
with other internal alkynes, both symmetrical and unsymmetrical,23 to produce a wider range of 
fully substituted triazoles. Transition metal-catalyzed cross-coupling36 using halogenated 
derivatives such as 41 should also provide modular access to numerous second-generation drug 
candidates for screening and optimization purposes. Further developments in these areas will be 
reported in due course. 
 
Experimental section 
Synthesis and characterization methods. All reactions were carried out in standard laboratory 
glassware with magnetic stirring. Thin layer chromatography (TLC) was performed on aluminum-
backed 0.20 mm silica gel plates. Visualization was accomplished with UV light, a ninhydrin 
staining solution in n-butanol and/or an aqueous ceric ammonium molybdate solution. Flash 
chromatography and silica pipette plugs were performed under positive air pressure using Silica 
Gel 60 of 230−400 mesh (40−63 µm). Optical Rotations were measured at 25 °C in the specified 
solvent with a path length of 1.0 dm on a Jasco P-2000 Digital Polarimeter (λ = 589 nm). 
Concentrations (c) are given in g/100 mL. Proton and carbon magnetic resonance spectra (1H 
NMR and 13C NMR) were recorded on a Varian Mercury 300 MHz spectrometer, a Varian Inova 
500 MHz spectrometer or a Varian VNMRS PS54 500 MHz spectrometer. Spectra aquired in 
CDCl3 are reported relative to tetramethylsilane (
1H:  = 0.00 ppm) and solvent resonance (13C:  
= 77.0 ppm). Spectra acquired in CD3OD are reported relative to solvent resonance (
1H:  = 3.31 
ppm; 13C:  = 49.0 ppm). 1H NMR data are reported as follows: chemical shift, multiplicity 
(abbreviations: s = singlet, bs = broad singlet, d = doublet, bd = broad doublet, app. d = apparent 
doublet, dd = doublet of doublets, t = triplet, app. t = apparent triplet, q = quartet, ABq = AB 
quartet, quin = quintet, sex = sextet, sep = septet, m = multiplet and bm = broad multiplet), 
coupling constant (Hz) and integration. Infrared (IR) spectra were obtained on a Shimadzu 
IRAffinity-1 FTIR Spectrometer. IR samples were analyzed as neat solids or oils. Low resolution 
mass spectrometry (MS) was performed on a Shimadzu LC-2010 Electrospray Ionization (ESI) 
Mass Spectrometer. All samples were prepared in HPLC grade methanol with a trace of formic 
acid. High resolution mass spectrometry (HRMS) was performed on a Waters Quadrupole-Time 
of Flight (QTOF) Xevo Spectrometer via ESI with Leucine-Enkephalin as an internal standard. 
For isolated hydrochloride salts of basic amino compounds, “M” refers to the mass of the 
corresponding neutral molecule. High performance liquid chromatography (HPLC) was 
performed on a reverse-phase phenomenex Synergi 4u Fusion-RP 80Å column (φ = 4.6 × 150 
mm) at a wavelength (λ) of 280 nm using water/acetonitrile (both containing 0.1% TFA) as the 
mobile phase. All samples were injected at a concentration of ~1 mg mL-1 in HPLC grade MeOH 
(injection volume = 20 µL). 
Synthesis materials. Nitrogen (N2) was dried by passage through self-indicating silica gel (2−4 
mm bead size). Unless otherwise noted, anhydrous solvents (obtained from commercial sources) 
were utilized. Known reagents and alkynes that were not commercially available were prepared 
according to literature procedures cited within the ESI†. All other reagents were purchased 
reagent grade and used as received. 
General synthetic procedures 
General procedure 1 for peptide coupling. A reaction vessel was charged in air with the 
carboxylic acid (1.0 equiv), EDCI·HCl (1.2 equiv), HOBt (1.2 equiv) and the specified 
equivalents of the amine. If the latter was an ammonium salt, a slight excess of (i-Pr)2NEt was 
also added as noted. To this was added the specified volume of HPLC grade MeCN (not pre-
dried) and the resulting mixture was stirred at rt in an air atmosphere for the time specified. After 
removal of the solvent under reduced pressure (for reactions with less than 5 mL of MeCN this is 
not necessary), the residue was dissolved in EtOAc (20 mL for reactions with ≤1 mmol of acid; or 
20 mL/mmol of acid for larger scale) and washed sequentially with 1 M HCl (2×20 mL; to 
remove any excess amine, EDCI and the urea by-product), saturated NaHCO3 (2×20 mL; to 
remove HOBt) and brine (20 mL). The organic layer was dried (MgSO4) and concentrated under 
 
 
reduced pressure, yielding in most cases the analytically pure peptide. Purification was carried out 
by flash chromatography with the indicated eluent if required. 
General procedure 2 for copper-catalyzed azide−alkyne cycloaddition. A reaction vessel was 
charged in air with the azide (1.0 equiv), Cu(OAc)2·H2O (0.2 equiv), Na·ascorbate (0.4 equiv), 
and the neat alkyne (3.0 equiv). To this was added t-BuOH (20 mL/mmol of azide) and H2O (5 
mL/mmol of azide). The mixture was sonicated briefly (<1 min) and the resulting suspension 
stirred at rt in an air atmosphere for the time specified. The mixture was diluted with EtOAc (20 
mL for reactions with ≤1 mmol of azide; or 20 mL/mmol of azide for larger scale) and shaken 
with a 1:1 mixture of 32% aqueous NH3:brine (20 mL). The organic layer was dried (MgSO4) and 
concentrated under reduced pressure. If required, the residue was purified using either a small 
silica pipette plug or conventional flash chromatography as specified, to give the desired 1,4-
substituted triazole. 
General procedure 3 for ruthenium-catalyzed azide−alkyne cycloaddition. An oven-dried vial 
was charged in air with the azide (1.0 equiv), Cp*RuCl(PPh3)2 (5 mol %) and the neat alkyne (2.0 
equiv). The vial was fitted with a rubber septum, evacuated and refilled with N2 (single cycle), 
then anhydrous 1,4-dioxane (10 mL/mmol of azide) was added. The sealed vessel was heated at 
60 °C under N2 for the specified time. After cooling to rt, the reaction mixture (with solvent) was 
directly subjected to flash chromatography with the specified eluent to provide the desired 1,5-
disubstituted- or 1,4,5-trisubstituted triazole. 
General procedure 4 for the preparation of alkyl ethers. To the neat alkyl alcohol (R'OH, 10 
equiv) under N2 at −78 °C was added a solution of NaHMDS (1 M in THF, 5 equiv) and the 
solution was stirred at −78 °C for 15 min to generate the sodium alkoxide. To this was added a 
solution of the mesylate (1 equiv) and NBu4I (0.1 equiv) in THF and the external cooling bath 
was allowed to warm to rt with stirring for the indicated time. The mixture was diluted with 
EtOAc (20 mL) and washed with 1 M HCl (20 mL) and saturated NaHCO3 (20 mL), then dried 
(MgSO4) and concentrated under reduced pressure. If required, purification was carried out by 
flash chromatography to provide the desired alkyl ether. 
General procedure 5 for TFA mediated deprotection. To a solution of the N-protected peptide 
in reagent grade CH2Cl2 (3.3 mL/0.1 mmol of substrate) was added TFA (3.3 mL/0.1 mmol of 
substrate) and the solution was stirred at rt in an air atmosphere for the time specified. The 
solvents were removed under reduced pressure and the residue dried under high vacuum. This 
was taken up in CH2Cl2 (~0.5 mL) and an aliquot of excess ethereal HCl (2 M in Et2O, 1.6 mL/0.1 
mmol of substrate) was added to exchange the TFA anion with chloride. The mixture was again 
concentrated and dried under reduced pressure. The remaining sticky solid was dissolved in 
minimal MeOH (≤10 drops from a Pasteur pipette for ≤0.05 mmol of product) and reagent grade 
Et2O (5 mL) was added, resulting in instantaneous precipitation of the product. The precipitate 
was collected via vacuum filtration and the original vessel (containing significant product 
deposited on the glass) and filter cake were washed with Et2O (3×10 mL). The filter cake was 
transferred back into the original vessel (containing the remainder of the product) via dissolution 
with MeOH (~10 mL). Concentration and drying under reduced pressure provided the desired 
hydrochloride salts as thin films which routinely gave easily-handled powders upon scratching 
with a spatula. 
 
Representative synthesis of compound 47 from acid 2 
tert-Butyl ((R)-6-(((R)-1-azido-5-(2-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl)guanidino)pentan-2-yl)amino)-5-(2-(((S)-2'-(isopentyloxy)-[1,1'-binaphthalen]-2-
yl)oxy)acetamido)-6-oxohexyl)carbamate (18). This compound was prepared according to 
general procedure 1 using the known acid 214 (1.806 g, 2.81 mmol), EDCI·HCl (646 mg, 3.37 
mmol), HOBt (455 mg, 3.37 mmol), amine 14 (1.266 g, 2.89 mmol) and MeCN (28 mL) with a 
4.5 h reaction time. Work-up as described gave 18 (2.899 g, 97%) as an off-white solid. TLC 
(10% MeOH/CH2Cl2) RF = 0.60, (75% EtOAc/pet. ether) RF = 0.68; 
25
D ][  −24.0 (c 5.31, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.97 (app. t, J = 9.4 Hz, 2H), 7.92–7.83 (m, 2H), 7.47 (d, J = 9.0 
Hz, 1H), 7.41–7.20 (m, 5H), 7.18–7.09 (m, 2H), 6.72 (d, J = 8.5 Hz, 1H), 6.17 (d, J = 7.6 Hz, 
1H), 6.07 (bs, 2H), 4.59 (t, J = 5.7 Hz, 1H), 4.45 (ABq, ΔδAB = 0.06, J = 14.5 Hz, 2H), 4.09–3.96 
(m, 2H), 3.96–3.85 (m, 2H), 3.30 (dd, J = 12.4, 4.5 Hz, 1H), 3.23 (dd, J = 12.4, 5.8 Hz, 1H), 
3.17–3.02 (m, 2H), 3.03– 2.84 (m, 4H), 2.56 (s, 3H), 2.50 (s, 3H), 2.08 (s, 3H), 1.51–1.31 (m, 
20H), 1.31–1.06 (m, 5H), 0.97–0.75 (m, 3H), 0.55 (d, J = 6.5 Hz, 3H), 0.50 (d, J = 6.5 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 171.4, 168.8, 158.6, 156.1, 155.9, 154.4, 152.1, 138.2, 133.8, 
133.6, 133.2, 132.1, 129.8, 129.75, 129.68, 129.2, 128.0, 127.9, 126.6, 126.5, 125.4, 124.9, 124.4, 
124.1, 123.7, 120.4, 119.3, 117.3, 115.9, 114.2, 86.2, 78.9, 68.3, 67.9, 54.6, 52.6, 48.8, 43.2, 40.5, 
40.0, 37.9, 31.1, 29.1, 28.5, 28.4, 25.6, 24.5, 22.4, 22.20, 22.16, 22.0, 19.2, 17.9, 12.4; IR (cm-1) ʋ 
3330, 2929, 2097, 1653, 1507, 1244, 1087, 808; MS (ES+) m/z 1085 (24%, M+Na), 1063 (100%, 







[1,1'-binaphthalen]-2-yl)oxy)acetamido)-6-oxohexyl)carbamate (22). This compound was 
prepared according to general procedure 2 using azide 18 (50.0 mg, 0.047 mmol), Cu(OAc)2·H2O 
(1.9 mg, 0.0094 mmol), Na·ascorbate (3.7 mg, 0.019 mmol), 1-octyne (15.6 mg, 0.14 mmol), t-
BuOH (1.0 mL) and H2O (0.25 mL) with a 24 h reaction time. Work-up as described gave 22 
(52.0 mg, 94%) as an off-white solid. TLC (100% EtOAc) RF = 0.10; 
25
D ][  −21.9 (c 2.45, 
CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.98–7.90 (m, 2H), 7.85 (app. t, J = 7.6 Hz, 2H), 7.44 (d, 
J = 8.9 Hz, 1H), 7.38 (s, 1H), 7.37–7.26 (m, 3H), 7.26–7.17 (m, 3H), 7.14 (d, J = 8.5 Hz, 1H), 
7.10 (d, J = 8.5 Hz, 1H), 6.27 (bs, 2H), 6.18 (bd, J = 5.7 Hz, 1H), 4.90 (bs, 1H), 4.48 (d, J = 14.5 
Hz, 1H), 4.41–4.27 (m, 3H), 4.25–4.16 (m, 1H), 4.07–3.95 (m, 2H), 3.93–3.85 (m, 1H), 3.15–3.04 
(m, 2H), 2.97–2.84 (m, 4H), 2.67 (t, J = 7.5 Hz, 2H), 2.55 (s, 3H), 2.48 (s, 3H), 2.07 (s, 3H), 
1.69–1.59 (m, 2H), 1.52–1.08 (m, 29H), 0.94–0.76 (m, 4H), 0.75–0.63 (m, 2H), 0.53 (d, J = 6.3 
Hz, 3H), 0.49 (d, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 171.5, 168.8, 158.6, 156.2, 
156.0, 154.3, 152.1, 148.1, 138.1, 133.8, 133.6, 133.0, 132.1, 129.7, 129.6, 129.1, 128.0, 127.9, 
126.6, 126.5, 125.4, 124.9, 124.5, 124.1, 123.7, 121.9, 120.3, 119.3, 117.4, 115.9, 114.2, 86.3, 
78.8, 68.2, 67.9, 52.8, 52.6, 49.2, 43.2, 40.5, 39.9, 37.9, 31.5, 31.0, 29.4, 29.02, 28.95, 28.5, 28.4, 
25.6, 25.3, 24.5, 22.5, 22.4, 22.2, 22.0, 19.2, 17.9, 14.0, 12.4; MS (ES+) m/z 1195 (100%, M+Na), 




This compound was prepared according to general procedure 5 using 22 (47.8 mg, 0.041 mmol), 
CH2Cl2 (1.34 mL) and TFA (1.34 mL) with a 24 h reaction time. Work-up and treatment with 
HCl (2 M in Et2O, 0.67 mL) as described gave 47 (34.2 mg, 94%) as a tan solid. 
25
D ][  −15.1 (c 
0.95, MeOH); 1H NMR (500 MHz, CD3OD) δ 8.18 (s, 1H), 8.03 (app. d, J = 9.0 Hz, 2H), 7.96– 
7.89 (m, 2H), 7.55 (d, J = 9.0 Hz, 1H), 7.49 (d, J = 9.0 Hz, 1H), 7.39–7.32 (m, 2H), 7.23 (app. t, J 
= 7.5 Hz, 2H), 7.12–7.02 (m, 2H), 4.70–4.41 (m, 4H), 4.34–4.25 (m, 1H), 4.18–4.08 (m, 1H), 
4.02–3.91 (m, 2H), 3.23–3.11 (m, 2H), 2.86–2.70 (m, 4H), 1.80–1.47 (m, 8H), 1.46–1.10 (m, 
10H), 1.07–0.97 (m, 1H), 0.96–0.79 (m, 5H), 0.58 (d, J = 6.5 Hz, 3H), 0.52 (d, J = 6.5 Hz, 3H); 
13C NMR (75 MHz, CD3OD) δ 173.7, 170.9, 158.5, 155.9, 154.1, 146.5, 135.2, 135.1, 131.4, 
130.8, 130.7, 129.3, 129.1, 127.6, 127.5, 126.3, 126.0, 125.2, 124.8, 121.7, 120.6, 116.8, 116.0, 
69.3, 69.0, 56.8, 53.9, 50.5, 41.8, 40.4, 39.3, 32.5, 32.2, 29.8, 29.6, 29.5, 27.7, 26.1, 25.6, 24.7, 
23.6, 23.5, 22.8, 22.5, 14.4; FTIR (cm-1) ʋ 2923, 1653, 1506, 1214, 1149, 1048, 811, 747; MS 
(ES+) m/z 821 (<5%, M+H), 411 (100%, M+2H); HRMS (ES+) Calcd. for C47H66N9O4: 820.5238 
(M+H), Found: 820.5256. 
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